Given the uncertain oncogenicity of KRAS G12C relative to KRAS G12D, we initiated tumors with several different titers of Lenti-D2G28-Pool/Cre (from 1.8 × 105 to 1.35 × 106 TU (transduction units)/mouse) and analyzed cohorts of mice at 9 and 15 weeks post-tumor initiation (Fig. 1B; n = between 9 and 35 mice per group). Here, KRAS is linked to neoplasm.